The Beat AML program, a functional genomics study of AML, suggests that patients with BCOR mutations show higher sensitivity to JAK inhibitors compared to those with BCOR wild-type, which remains to be confirmed in future studies [26]. Here, BCOR is linked to acute myeloid leukemia.